tris(tributylammonium) phosphate | 29306-76-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: tris(tributylammonium) phosphate
• 英文别名: tributylammonium phosphate；tri-n-butylammonium phosphate；Phosphoric acid--N,N-dibutylbutan-1-amine (1/1)；N,N-dibutylbutan-1-amine;phosphoric acid
• CAS: 29306-76-1
• 化学式: 3C₁₂H₂₇N*H₃O₄P
• 分子量: 654.054
• InChiKey: OJVWCPKLFCTIPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.76
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  85
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  sodium;[(2R,3S,4R,5R)-5-(5,8-dioxo-6,7-dihydro-4H-imidazo[4,5-e][1,4]diazepin-3-yl)-3,4-dihydroxyoxolan-2-yl]methyl morpholin-4-yl phosphate 、 tris(tributylammonium) phosphate 生成 trisodium;[[(2R,3S,4R,5R)-5-(5,8-dioxo-6,7-dihydro-4H-imidazo[4,5-e][1,4]diazepin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate
  参考文献：
  名称：

  HOSMANE, RAMACHANDRA S.;BHAN, ANILA;KARPEL, RICHARD L.;SIRIWARDANE, UPALI+, J. ORG. CHEM., 55,(1990) N3, C. 5882-5890

  摘要：

  DOI：
• 作为产物：
  描述：

  Pyrophosphoric chloride 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 生成 tris(tributylammonium) phosphate
  参考文献：
  名称：

  NUCLEIC ACID AMPLIFICATION AND SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES

  摘要：

  一般来说，该发明涉及基于在微反应器中测量荧光核苷酸的结合而进行核酸测序的方法和系统。该发明相比先前系统具有诸多优势，如序列的明确确定、快速循环时间、长读取长度、低试剂总成本、低仪器成本和高吞吐量。该发明还涉及核酸扩增的方法和试剂盒。该发明的扩增和测序方面可以单独或结合使用。该发明还涉及可用于该测序方法的荧光核苷酸。

  公开号：

  US20130053252A1
• 作为试剂：
  描述：

  adenosine dichlorophosphate 在 tris(tributylammonium) phosphate 、 三正丁胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.02h， 生成 adenosine 5'-triphosphate
  参考文献：
  名称：

  A novel synthesis of nucleoside 5′-triphosphates

  摘要：

  已经实现了核糖核苷酸5'-三磷酸的便捷合成，通过将未保护的核苷与磷酰氯进行一锅反应，然后在使用二甲基甲酰胺存在的条件下，用三正丁基铵磷酸盐处理生成的磷酸二氯酯，可以良好收率（>60%）获得目标产物。

  DOI：

  10.1039/c39910001276

文献信息

• [EN] NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO<br/>[FR] COMPOSITIONS À BASE DE NUCLÉOTIDE ET DE NUCLÉOSIDE ET UTILISATIONS CORRESPONDANTES
  申请人：UNIV EMORY

  公开号：WO2015038596A1

  公开（公告）日：2015-03-19

  This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

  这份披露涉及到核苷酸和核苷类治疗组合物，用于治疗传染病、病毒感染和癌症，在这些组合物中，核苷酸或核苷的碱基至少含有一个硫醇、硫酮或硫醚。
• Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
  申请人：——

  公开号：US20020147160A1

  公开（公告）日：2002-10-10

  The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

  本发明提供了核苷化合物及其某些衍生物，这些衍生物是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂，可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒（HCV）NS5B聚合酶的抑制剂，作为HCV复制的抑制剂，以及/或用于治疗丙型肝炎感染。本发明还描述了包含这种核苷化合物的药物组合物，单独使用或与其他对RNA依赖性RNA病毒感染，特别是HCV感染有效的制剂组合使用。还公开了使用本发明的核苷化合物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• [EN] NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES RENFERMANT DES NUCLÉOTIDES ET DES NUCLÉOSIDES ET UTILISATIONS ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2016145142A1

  公开（公告）日：2016-09-15

  This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

  这份披露涉及到核苷酸和核苷类治疗组合物，用于治疗传染病、病毒感染和癌症，其中核苷酸或核苷的碱基至少含有一个硫醇、硫醌或硫醚。
• New modified nucleoside 5′-triphosphates: synthesis, properties towards DNA polymerases, stability in blood serum and antiviral activity
  作者：Alexander V. Shipitsin、Lyubov S. Victorova、Elena A. Shirokova、Natalya B. Dyatkina、Lyudmila E. Goryunova、Robert Sh. Beabealashvilli、Chris J. Hamilton、Stanley M. Roberts、Alexander Krayevsky

  DOI：10.1039/a900336c

  日期：——

  A series of new nucleoside 5′-triphosphate mimetics, 2, 3, 5, 6, 8–10, modified at the glycone and all three phosphate residues, have been synthesised and studied. These compounds only bear the enzymatically labile anhydride bond between the α and β phosphorus atoms. The preparative chemistry involved the preparation of phosphonic salts 30, 31 and 32 and coupling of these species to the morpholidate 33. The mechanism of formation of some of the intermediates ‘en route’ to 27 and 28 is discussed. All of the target compounds demonstrated high stability in human blood serum with half lives towards hydrolysis of up to 4.5 days. Some of these nucleoside triphosphonates have been shown to be selective inhibitors of DNA synthesis catalysed by retroviral reverse transcriptases and terminal deoxynucleotidyl transferases. They inhibited replication of the artificial virus containing Moloney murine leukemia virus reverse transcriptase in infected cell culture, probably due to the inhibition of a reverse transcription step of a genomic RNA. Compared to the triphosphonates, the corresponding monophosphonates demonstrated decreased antiviral activity by 1–2 orders of magnitude. This implies that the triphosphonates inhibit virus replication directly, rather than by a two-step mechanism based on their hydrolysis to the monophosphonates and subsequent intracellular diphosphorylation. Being totally independent of the enzymatic phosphorylation pathways of the host cell, the compounds under study may also be able to inhibit retrovirus reproduction both in kinase deficient cell lines and in the intercellular blood media.

  一系列新的核苷5'-三磷酸盐类似物2、3、5、6、8-10在糖基和所有三个磷酸盐残基处进行了修饰，已被合成并研究。这些化合物仅具有α和β磷原子之间的酶促不稳定的酐键。涉及的制备化学包括制备膦酸盐30、31和32以及将这些物种与吗啉代33耦合。讨论了形成一些中间体形成27和28的机制。所有目标化合物在人体血清中表现出高稳定性，水解半衰期长达4.5天。一些这些核苷三磷酸盐已被证明是对逆转录病毒逆转录酶和终端脱氧核苷酸转移酶催化的DNA合成的选择性抑制剂。它们抑制了感染细胞培养中包含Moloney鼠白血病病毒逆转录酶的人工病毒的复制，这可能是由于基因组RNA的逆转录步骤被抑制。与三磷酸盐相比，相应的单磷酸盐的抗病毒活性降低了1-2个数量级。这意味着三磷酸盐直接抑制病毒复制，而不是通过先水解为单磷酸盐然后细胞内二磷酸化的两步机制。由于完全独立于宿主细胞的酶促磷酸化途径，所研究的化合物也可能在缺乏激酶的细胞系和细胞间血液介质中抑制逆转录病毒的繁殖。
• New thymidine triphosphate analog inhibitors of human immunodeficiency virus-1 reverse transcriptase.
  作者：Qi Feng Ma、Ian C. Bathurst、Philip J. Barr、George L. Kenyon

  DOI：10.1021/jm00089a002

  日期：1992.5

  Several novel imidotriphosphate analogues of thymidine have been synthesized and have been shown to be effective inhibitors of human immunodeficiency virus-1 reverse transcriptase (HIV-1 RT). When the alpha,beta-bridging oxygens of thymidine triphosphate (TTP) and 3'-azido-3'-deoxythymidine 5'-triphosphate (AZTTP) were replaced by a nitrogen, the resulting analogues were no longer substrates but instead

  已合成了胸腺嘧啶的几种新型亚氨基三磷酸类似物，并已证明是人类免疫缺陷病毒1逆转录酶（HIV-1 RT）的有效抑制剂。当胸苷三磷酸（TTP）和3'-叠氮基3'-脱氧胸苷5'-三磷酸（AZTTP）的α，β桥接氧被氮取代时，所得类似物不再是底物，而是成为竞争性抑制剂HIV-1 RT。测试的最有效的α，β-亚氨基三磷酸衍生物是胸苷5'-α，β-亚氨基三磷酸（TMPNPP，1a）。该类似物的Ki值为2.4 microM，与抑制DNA聚合酶I大片段（Klenow）相比，对HIV-1 RT的抑制作用更强400倍。3'-叠氮基3'-脱氧胸苷5'-α，β-亚氨基三磷酸（AZTMPNPP，1b）的Ki值比TMPNPP大10倍，表明3'-叠氮基取代基相对于正常的3'-OH取代基降低了AZTTP对HIV-1 RT的亲和力。脱氧胸苷5'-α，β-亚氨基三磷酸酯（ddTMPNPP，1c）的效力中等，Ki值为15 mi